Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
58.35B
Market cap58.35B
Price-Earnings ratio
1.84K
Price-Earnings ratio1.84K
Dividend yield
Dividend yield
Average volume
1.23M
Average volume1.23M
High today
$449.68
High today$449.68
Low today
$440.93
Low today$440.93
Open price
$445.00
Open price$445.00
Volume
739.03K
Volume739.03K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $449.50. The company's market cap stands at 58.35B, with a P/E ratio of 1841.51.

As of 2025-11-11, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $440.93 and $449.68. The current price stands at $449.50, placing the stock +1.9% above today's low and -0.0% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 739.03K, compared to an average daily volume of 1.23M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

ALNY News

Nasdaq 14h
Validea Detailed Fundamental Analysis - ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Mome...

Validea Detailed Fundamental Analysis - ALNY
TipRanks 2d
Alnylam announces results from post hoc analyses of HELIOS-B Phase 3 study

Alnylam (ALNY) Pharmaceuticals announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA, an RNAi therapeutic approved for the trea...

Simply Wall St 2d
Alnylam Pharmaceuticals: Assessing Valuation Following New HELIOS-B Data and Upbeat Financial Results

Alnylam Pharmaceuticals (ALNY) shared new results from its Phase 3 HELIOS-B study of vutrisiran, with data presented at the American Heart Association meeting....

Alnylam Pharmaceuticals: Assessing Valuation Following New HELIOS-B Data and Upbeat Financial Results

Analyst ratings

71%

of 31 ratings
Buy
71%
Hold
25.8%
Sell
3.2%

More ALNY News

Simply Wall St 4d
How Investors May Respond To Alnylam Pharmaceuticals Surging Revenue and Raised 2025 Guidance

Alnylam Pharmaceuticals recently reported that third-quarter revenue rose to US$1.25 billion from US$500.92 million a year earlier, swinging from a net loss to...

How Investors May Respond To Alnylam Pharmaceuticals Surging Revenue and Raised 2025 Guidance
Simply Wall St 6d
Is Alnylam Pharmaceuticals Fairly Priced After FDA Approval Drives 81.3% Rally in 2025?

Wondering if Alnylam Pharmaceuticals is actually good value right now? You are not alone, especially with all the hype and debate around biotech stocks lately....

Is Alnylam Pharmaceuticals Fairly Priced After FDA Approval Drives 81.3% Rally in 2025?

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.